1. Summary of outcome data.

Study	Interventions	wound healing	adverse events	Wound size (change)	Infection status or resistance (change)	Pain	Resource use	Costs
Barrois 1993	Povidone iodine Hydrocolloid	9/38 vs 10/38	0/38 vs 0/38				Dressings/week 5.07 vs 2.43 (SD not reported)
Chuangsuwanich 2011	Silver mesh Silver sulfadiazine		0/20 vs 0/20	20.1% vs 34.6% reduction (SD not reported; N = 20 in both groups)				USD 263 vs USD 1812 (SD not reported)
Chuangsuwanich 2013	Silver alginate Silver sulfadiazine			51.7% (N = 13) vs 44.27% (N = 15) reduction (SD not reported)				USD 377.17 vs USD 467.74 (SD not reported)
Imamura 1989	Povidone iodine sugar Lysozyme ointment	15/72 vs 12/69	1/72 vs 3/69		28/61 vs 17/61 improved
Kaya 2005	Povidone iodine Hydrogel	13/24 vs 21/25 ulcers
Kucan 1981	Povidone iodine Silver sulfadiazine Saline				7/11 vs 15/15 vs 11/14 resolved
Moberg 1983	Cadexomer iodine Standard care	6/19 vs 1/19	5/14 vs 0/13
Nisi 2005	Povidone iodine Protease‐modulating matrix	28/40 vs 36/40		76.2% (SE 8.2; n = 14) vs 57.4% (SE 9.4; n = 13) reduction		3.1 (SE 1.7) vs 7.5 (SE 2.8)	hospital stay: 1164 vs 360 days dressing use; 14 to 52 vs 6 to 15
Sipponen 2008	Spruce resin salve Hydrocolloid	17/27 vs 4/18			1/18 vs 1/18 infected/resolved
Toba 1997	Povidone iodine sugar Gentian violet			44.3% vs 55.4% reduction (decrease to 55.7 (24.0)% vs decrease to 44.6 (12.9)%	8/11 vs 7/8 no longer MRSA affected
Wild 2012	Polyhexanide dressing Polyhexanide swabs				15/15 vs 10/15 no longer MRSA affected	1.3 (0.36) vs 3.33 (1.2)	Dressing change time: 6 vs 25 min (SD not reported)
Yapucu Güneş 2007	Honey Ethoxy‐diaminoacridine plus nitrofurazone	5/25 vs 0/≥26 ulcers	0/15 vs 0/11	56% vs 13% reduction (SD not reported)